## Ghana

### Tuberculosis profile

#### Population 2018
- 30 million

#### Estimates of TB burden*, 2018
<table>
<thead>
<tr>
<th></th>
<th>Number (thousands)</th>
<th>Rate (per 100 000 population)</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Total TB incidence</strong></td>
<td>44 (21–75)</td>
<td>148 (72–251)</td>
</tr>
<tr>
<td><strong>HIV-positive TB incidence</strong></td>
<td>8.6 (4.1–15)</td>
<td>29 (14–49)</td>
</tr>
<tr>
<td><strong>MDR-RR-TB incidence</strong></td>
<td>0.87 (0.41–1.5)</td>
<td>2.9 (1.4–5)</td>
</tr>
<tr>
<td><strong>HIV-negative TB mortality</strong></td>
<td>11 (4.8–19)</td>
<td>36 (16–64)</td>
</tr>
<tr>
<td><strong>HIV-positive TB mortality</strong></td>
<td>4.8 (2.3–8.1)</td>
<td>16 (7.7–27)</td>
</tr>
</tbody>
</table>

#### Estimated proportion of TB cases with MDR/RR-TB, 2018
<table>
<thead>
<tr>
<th>Event</th>
<th>Incidence</th>
<th>(Range)</th>
</tr>
</thead>
<tbody>
<tr>
<td>New cases</td>
<td>1.3% (1–1.6)</td>
<td></td>
</tr>
<tr>
<td>Previously treated cases</td>
<td>16% (14–19)</td>
<td></td>
</tr>
</tbody>
</table>

#### TB case notifications, 2018
- **Total new and relapse**: 13,874
- **- % tested with rapid diagnostics at time of diagnosis**: 60%
- **- % with known HIV status**: 93%
- **- % pulmonary**: 92%
- **- % bacteriologically confirmed**: 66%
- **- % children aged 0-14 years**: 6%
- **- % women**: 30%
- **- % men**: 64%

#### Universal health coverage and social protection
- **TB treatment coverage (notified/estimated incidence), 2018**: 32% (19–65)
- **TB patients facing catastrophic total costs, 2016**: 64% (61–68)
- **TB case fatality ratio (estimated mortality/estimated incidence), 2018**: 39% (14–68)

#### TB/HIV care in new and relapse TB patients, 2018
- **Number (%):**
  - Patients with known HIV status who are HIV-positive: 2,509 (19%)
    - **- on antiretroviral therapy**: 1,155 (46%)

#### Drug-resistant TB care, 2018
- **% of bacteriologically confirmed TB cases tested for rifampicin resistance**
  - New cases: 93%
  - Previously treated cases: 100%

#### Laboratory-confirmed cases*
- MDR/RR-TB: 231
- XDR-TB: 1

#### Patients started on treatment**
- MDR/RR-TB: 147
- XDR-TB: 1

#### MDR/RR-TB cases tested for resistance to second-line drugs
- 68

#### Treatment success rate and cohort size
- **Success Cohort**:
  - New and relapse cases registered in 2017: 86% 14,121
  - Previously treated cases, excluding relapse, registered in 2017: 82% 429
  - HIV-positive TB cases registered in 2017: 77% 2,759
  - MDR/RR-TB cases started on second-line treatment in 2016: 82% 77
  - XDR-TB cases started on second-line treatment in 2016: 0

#### TB preventive treatment, 2018
- **% of HIV-positive people (newly enrolled in care) on preventive treatment**: 77%
- **% of children (aged < 5) household contacts of bacteriologically-confirmed TB cases on preventive treatment**: 6%

#### TB financing, 2019
- **National TB budget (US$ millions)**: 20
  - Funding source: 13% domestic, 47% international, 40% unfunded

---

*Ranges represent uncertainty intervals

** MDR is TB resistant to rifampicin and isoniazid; RR is TB resistant to rifampicin

*** Calculated for pulmonary cases only

* Includes cases with unknown previous TB treatment history

** Includes patients diagnosed before 2018 and patients who were not laboratory-confirmed

---

Data are as reported to WHO. Estimates of TB and MDR-TB burden are produced by WHO in consultation with countries.
Generated: 2020-03-19